Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinco Pharmaceuticals Holdings Limited
兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the "**Board**") of directors (the "**Directors**") of Sinco Pharmaceuticals Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Mr. Dong Yingjie ("**Mr. Dong**") and Mr. Ye Guowei ("**Mr. Ye**"), have been appointed as independent non-executive Directors of the Company with effect from 28 August 2026.

The brief biographical details of Mr. Dong are set out below:

Mr. Dong, aged 63, possesses over 37 years of experience in the pharmaceutical industry. Mr. Dong is currently a part-time engineer in Liaoning Wanjia Pharmaceutical Technology Co., Ltd. (遼寧萬嘉醫藥科技有限公司). Mr. Dong served as a chief pharmacist in the Liaoning Institute of Pharmaceutical Research Center (遼寧省藥物研究院) from September 1989 to September 2017 and as a chief pharmacist in Liaoning Inspection, Testing and Certification Centre (遼寧省檢驗檢測認證中心) from September 2017 until his retirement in April 2023. From August 2018 to August 2023, Mr. Dong served as a part-time professor at the School of Functional Food and Wine of Shenyang Pharmaceutical University (瀋陽藥科大學).

Mr. Dong obtained a bachelor degree in agriculture and a master degree in agriculture from Jilin Agricultural University (吉林農業大學) in 1986 and 1989, respectively. Mr. Dong was also recognised as a Chief Pharmacist (主任藥師) by Liaoning Provincial Personnel Department (遼寧省人事廳) in September 2008.

Mr. Dong's appointment has been recommended by members of the nomination committee of the Company (the "**Nomination Committee**") and approved by the Board. Pursuant to the letter of appointment between Mr. Dong and the Company, the term of service of Mr. Dong shall be three years commencing on 28 August 2026, subject to retirement by rotation and re-election in accordance with the articles of association of the Company (the "**Articles of Association**"), and Mr. Dong will be entitled to a director's fee of RMB300,000 per annum, which has been recommended by the remuneration committee of the Board (the "**Remuneration Committee**") and proposed by the Board with reference to, among other things, (i) his duties and responsibilities within the Company; (ii) the prevailing market conditions; and (iii) his qualifications and experience. Mr. Dong has confirmed that he met the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Save as disclosed above, as at the date of this announcement, Mr. Dong:

(i) did not hold any position in the Company or other members of the Company;

(ii) did not involve or have any material interest in any principal business activity with the Company;

(iii) did not hold any directorship in any public companies, the securities of which are listed in Hong Kong or overseas, in the last three years preceding the date of this announcement;

(iv) did not have any interest in any shares of the Company (the "**Shares**") or underlying Shares or any debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and

(v) was not connected and had no relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined in the Listing Rules).

Mr. Dong has confirmed that (i) he has satisfied all the criteria for independence as set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. Considering all of the circumstances described above, the Board considers that Mr. Dong is independent.

Further, save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Dong that need to be brought to the attention of the shareholders of the Company.

The brief biographical details of Mr. Ye are set out below:

Mr. Ye, aged 63, possesses over 40 years of experience in the pharmaceutical industry. Mr. Ye is the founder of Fujian Ruilaichuntang Traditional Chinese Medicine Clinic Chain Enterprise (福建瑞來春堂基層中醫連鎖企業) since January 2010. Mr. Ye worked at Fuzhou Medicinal Materials Procurement and Supply Station (福州藥材採購供應站) as a technician from August 1986 to December 1988, as an officer of the traditional Chinese medicine department from January 1989 to December 1994, and as deputy manager from January 1995 to December 1997. From January 1998 to December 2002, he served as general manager of the Traditional Chinese Medicine Branch of Fujian Tongchun Pharmaceutical Co., Ltd. (福建同春藥業股份有限公司中藥分公司), and as deputy general manager of Fujian Tongchun Pharmaceutical Co., Ltd. (福建同春藥業股份有限公司) and general manager of its Traditional Chinese Medicine Branch, concurrently serving as chairman of the board of Huichun Traditional Chinese Medicine Herbal Pieces Factory (回春中藥飲片廠) and a core member of the hospital business department of the Pharmaceutical Bidding Office (同春藥品招標辦) from January 2003 to December 2006. From January 2007 to December 2009, he served as deputy general manager of Gansu Provincial Medicinal Materials Company (甘肅省藥材公司).

Mr. Ye obtained a bachelor degree in agriculture from Jilin Agricultural University (吉林農業大學) in 1986. Mr. Ye was also recognised as a mid-level Chief Pharmacist of Traditional Chinese Medicine (主管中藥師) in January 2003.

Mr. Ye's appointment has been recommended by members of the Nomination Committee and approved by the Board. Pursuant to the letter of appointment between Mr. Ye and the Company, the term of service of Mr. Ye shall be three years commencing on 28 August 2026, subject to retirement by rotation and re-election in accordance with the Articles of Association, and Mr. Ye will be entitled to a director's fee of RMB300,000 per annum, which has been recommended by the Remuneration Committee and proposed by the Board with reference to, among other things, (i) his duties and responsibilities within the Company; (ii) the prevailing market conditions; and (iii) his qualifications and experience. Mr. Ye has confirmed that he met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, as at the date of this announcement, Mr. Ye:

(i) did not hold any position in the Company or other members of the Company;

(ii) did not involve or have any material interest in any principal business activity with the Company;

(iii) did not hold any directorship in any public companies, the securities of which are listed in Hong Kong or overseas, in the last three years preceding the date of this announcement;

(iv) did not have any interest in any Shares or underlying Shares or any debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and

(v) was not connected and had no relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined in the Listing Rules).

Mr. Ye has confirmed that (i) he has satisfied all the criteria for independence as set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he had no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. Considering all of the circumstances described above, the Board considers that Mr. Ye is independent.

Further, save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Ye that need to be brought to the attention of the shareholders of the Company.

The Board extends its warm welcome to Mr. Dong and Mr. Ye for joining the Company.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Zhijian
Chairman and executive Director

Sichuan, the PRC, 28 August 2026

As at the date of this announcement, the executive Directors are Mr. Huang Zhijian and Mr. Lei Shifeng; the Non-executive Director is Ms. Jing Huan; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang, Mr. Bai Zhizhong, Mr. Dong Yingjie and Mr. Ye Guowei.